Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Powered by its popular GLP-1 weight loss drugs, Eli Lilly's stock (NYSE: LLY) has had a strong run this year, up more than 55 ...

Eli Lilly is set to report Q3 earnings Wednesday, as the pharma giant continues to gain market share in the weight loss drug ...

Eli Lilly LLY will report its third-quarter 2024 earnings on Oct. 30, before market open. The Zacks Consensus Estimate for ...

Eli Lilly (LLY) announced “positive results” from the TRAILBLAZER-ALZ 6 Phase 3b study, showing a reduction in amyloid-related ...

Pfizer (PFE) offered up some more details on its weight loss drug pipeline on Tuesday during a call with investors after it ...

Over the last 3 months, EPS estimates have seen 0 upward revisions and 13 downward. Revenue estimates have seen 16 upward ...

Eli Lilly reports Q3 earnings on Wednesday. Stock up 58% in past year, potential to split to attract investors in growing ...

Eli Lilly (LLY) expects to start selling its weight-loss drug tirzepatide, branded as Mounjaro, in Hong Kong as early as the ...

The pursuit of thinness, especially for young girls, has come at a great cost. Read more at straitstimes.com.

Novo Nordisk A/S has fallen behind Eli Lilly & Co. this year in the race to be the big stock market winner from obesity drugs ...